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Development of new therapeutic approach to treat leishmaniasis has become a priority.
In the present study, the antileishmanial effect of β-nitrostyrenes was investigated
against in vitro promastigotes and amastigotes. A series of β-nitrostyrenes have been
synthesized by using Henry reaction and were evaluated for their antimicrobial activities
by broth microdilution assay and in vitro antileishmanial activities against Leishmania
donovani promastigotes by following standard guidelines. The most active compounds
were futher evaluated for their in vitro antileishmanial activities against intracellular
amastigotes. Among the tested β-nitrostyrenes, compounds 7, 8, 9, 12, and 17
exhibited potential activities (MICs range, 0.25–8µg/mL) against clinically significant
human pathogenic fungi. However, the microbactericidal concentrations (MBCs) and the
microfungicidal concentrations (MFCs) were found to be either similar or only two-fold
greater than the MICs. Anti-leishmanial results demonstrated that compounds 9, 12, 14,
and 18 were found to be most active among the tested samples and exhibited 50%
inhibitory concentration (IC50) by 23.40 ± 0.71, 37.83 ± 3.74, 40.50 ± 1.47, 55.66 ±
2.84 nM against L. donovani promastigotes and 30.5 ± 3.42, 21.46 ± 0.96, 26.43 ±
2.71, and 61.63 ± 8.02 nM respectively against intracellular L. donovani promastigotes
amastigotes respectively which are comparable with standard AmB (19.60 ± 1.71 nM
against promastigotes and 27.83 ± 3.26 nM against amastigotes). Compounds 9, 12,
14, and 18 were found to have potent in vitro leishmanicidal activity against L. donovani
and found to be non-toxic against mammalian macrophages even at a concentration of
25µM. Nitric oxide (NO) estimation studies reveals that these compounds aremoderately
inducing NO levels.
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INTRODUCTION
Leishmaniasis is a complex infection caused by multiple species of the intracellular protozoan
parasites of genus Leishmania and is transmitted by the bite of a female phlebotomine sand fly
vector. The disease is endemic in 82 countries of tropical and subtropical areas around the world
and affects an estimated 12 million people with 2 million new cases annually (Davies et al., 2003;
Murray et al., 2005; WHO, 2005, 2007a; Piscopo and Azzopardi, 2007). It is one of the most
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neglected tropical diseases, with a major impact among the
poorest. Visceral leishmaniasis (VL) is also known as kala-azar
(black fever) in the Indian sub-continent which is the most
severe form of the disease, is being fatal if untreated (WHO,
1999; Gour et al., 2009). In non-endemic areas of the world, VL
is mostly an opportunistic infection and often associated with
human immunodeficiency virus (HIV) infection (WHO, 2007b,
2010).
The number of leishmaniasis cases is increasing worldwide
due to the lack of safe and effective drug, vaccines, difficulty in
controlling vectors and mounting parasite resistance. From the
1940s, pentavalent antimonials (Sodium antimony gluconate-
SAG, sodium stibogluconate-pentostam, and meglumine
antimoniate-glucantime) are being used to prevent leishmaniasis
since their discovery (Croft et al., 2005; Mishra et al., 2007;
Santos et al., 2008). These drugs are highly toxic and require
prolonged treatments with parenteral administration (Croft
et al., 2005; WHO, 2010). Further the escalating antimonials
resistance to strains of Leishmania donovani in India, makes
most of the cases un-responsive to treatment (Croft et al., 2005;
Gour et al., 2009). The inefficacy of antimonials is particularly
prominent in HIV-Leishmania co-infections (Croft et al., 2005;
Mishra et al., 2007). Over the past decades, few alternative
drugs including pentamidine, isethionate, amphotericin B,
paromomycin, miltefosine have been developed. But none of
them are ideal for treatment due to high toxicity, resistance,
exorbitant prices, prolonged treatment and inadequate mode
of administration (Davies et al., 2003; Kayser et al., 2003; Croft
et al., 2005; Alvar et al., 2006; Mishra et al., 2007; Santos et al.,
2008; Sundar et al., 2011). The adverse effects and unaffordable
prices of the current drugs divulge an urgent need for new, safer,
effective, and cheaper alternates (Kayser et al., 2003).
Evaluation of antimicrobial agents against leishmanial
parasites is being one of the promising approaches in the
leishmanial drug discovery. Antifungal agents have shown
some positive results in this prospective (Verma et al., 2011;
Ibrahim et al., 2012). Azole antifungal agents have been used as
antileishmanial agents since 1980s, (Saenz et al., 1990; Alrajhi
et al., 2002; Kashani et al., 2005; Murray et al., 2005) but their use
in the treatment of cutaneous and VL has produced inconsistent
results (Weinrauch et al., 1987; Beach et al., 1988; Hart et al.,
1989; Wali et al., 1990; Urbina, 1997; Al-Abdely et al., 1999).
Further in 1981, New et al. investigated parasiticidal activity
of a number of anti-fungal agents including: griseofulvin,
5-fluorocytosine, and amphotericin B against VL (New et al.,
1981). Amphotericin B is emerged as a standalone drug which
is the only drug in clinical use for VL. But the adverse effects
and increasing resistance of Amphotericin B stating the need
for the development of new chemical entities. In this regard
we focused at the development of natural product based new
anti-leishmanial agents from the known anti-fungal agents.
β-nitrostyrenes have been known for their antimicrobial
activities over the past few decades (Brian et al., 1946; Schales
and Graefe, 1952; Evans et al., 1956; Huitric et al., 1956; Worthen
and Bond, 1970; Mikami et al., 1987, 1991; Denisenko et al.,
2004; Milhazes et al., 2006; Al-Zereini et al., 2007; Pettit et al.,
2009; Lo et al., 2012). Their antifungal properties have also been
FIGURE 1 | Naturally occurring β-nitrostyrenes.
known over the years and demonstrated a broad spectrum of
activities against various fungal strains (Schales and Graefe, 1952;
Evans et al., 1956; Huitric et al., 1956; Mikami et al., 1987, 1991;
Al-Zereini et al., 2007; Pettit et al., 2009).
β-nitrostyrenes have been rarely found in nature. 3,4-
dihydroxy-β-nitrostyrene (SL-1), a reddish brown compound
was isolated from Streptomyces lavendulaea (Mikami et al., 1987).
2-nitro-4-((E)-2-nitrovinyl)phenol, an another β-nitrostyrene
has been isolated from an Indian mangrove plant Sonneratia
acids Linn. F (Mikami et al., 1991). The same β-nitrostyrene
has been further isolated from Salegentibacter sp. T436 an Artic
sea ice bacterium (Al-Zereini et al., 2007). Both the natural
β-nitrostyrenes (Figure 1) and their synthetic derivatives were
found to exhibit a wide range of antibacterial and antifungal
activities (Brian et al., 1946; Schales and Graefe, 1952; Evans
et al., 1956; Huitric et al., 1956; Worthen and Bond, 1970;
Mikami et al., 1987, 1991; Denisenko et al., 2004; Milhazes
et al., 2006; Al-Zereini et al., 2007; Pettit et al., 2009; Lo et al.,
2012).
Apart from the antimicrobial properties, some β-nitrostyrene
derivatives found to be anti-proliferative agents (Carter et al.,
2002; Kaap et al., 2003), selective human telomerase inhibitors
(Kim et al., 2003), antiplatelet (Hsieh et al., 2010) agents and
NLRP3 activation inhibitors (He et al., 2014). The nitrovinyl side
chain attached to the aromatic ring was recognized to be an
essential chemical feature in this type of compounds and a critical
conformational pattern for their biological activity (Evans et al.,
1956; Huitric et al., 1956; Mikami et al., 1987, 1991; Milhazes
et al., 2006; Al-Zereini et al., 2007).
The promising antifungal properties of β-nitrostyrenes and
the morphological similarities of fungi with leishmanial parasite
prompted us to evaluate the anti-leishmanial potential of β-
nitrostyrenes and to develop a structure activity relationship
(SAR) around this nitrovinyl moiety. In the present report we
are presenting the anti-leishmanial potential of β-nitrostyrenes
for the first time.
MATERIALS AND METHODS
Animals
BALB/c mice was used for the isolation of peritoneal
macrophages in the ex vivo anti-amastigote study after prior
approval from the Jamia Hamdard Animal Ethics Committee
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(JHAEC). JHAEC is registered under the Committee for the
purpose of supervision and control of experiments on animals
(CPCSEA). Mice were individually housed in the Central Animal
House of Jamia Hamdard as per internationally accepted norms.
The mice were kept in standard size polycarbonate cages under
controlled conditions of temperature (23 ± 1◦C), humidity (55
± 10%), 12:12 h of light and dark cycle and fed with standard
pellet diet and filtered water (ad libitum).
Materials
All commercial chemicals used as starting materials and reagents
in this study were purchased from Merck (India), Spectrochem,
and Sigma Aldrich which were of reagent grade. All melting
points were uncorrected and measured using Electro-thermal
IA 9100 apparatus (Shimadzu, Japan); IR spectra were recorded
on Bruker ALPHA FT-IR spectrometer (Germany), 1H- NMR
spectra were determined on a Bruker (300 and 400MHz)
spectrometer and chemical shifts were expressed as ppm against
TMS as internal reference. Mass spectra were recorded on 70 eV
(EIMs-QP 1000EX, Shimadzu, Japan), ColumnChromatography
was performed on (Merck) Silica gel 60 (particle size 0.06e
0.20mm).
General Procedure for the Synthesis of
β-Nitrostyrenes
All the nitrostyrenes were synthesized using the known
Henry reaction. To the stirred solution of acetic acid (5mL)
and ammonium acetate (20 eq to aldehyde) was added
nitromethane/nitroethane/nitropropane (2 eq to aldehyde)
followed by aromatic aldehyde (1 eq) and the solution was
refluxed in an oil bath at 110◦C for 6-8 h. After the clearance
of TLC, the total dark solution was distilled under vacume
completely brown colored syrup obtained, the syrup was poured
in crushed ice and product was extracted with ethyl acetate
(50mL × 3), the combined organic layer dried over Na2SO4.
The combined organic layers were evaporated under vacuum
to afford the impure reaction mixture which was purified
by column chromatography (silica gel) to obtain the pure
β-nitrostyrene.
1. 1-chloro-4-((E)-2-nitrovinyl) benzene (1) (Kumar et al.,
2012): IR (cm−1): 3092, 2959, 2348, 1624, 1484, 1398, 1330,
1251, 1077, 965, 812, 735; 1H NMR (DMSO-D6,300 MHz):
δ 7.53 (d, J = 8.4Hz, 2H), 7.86 (d, J = 8.7Hz, 2H), 8.11 (d,
J = 13.8Hz, 1H), 8.23 (d, J = 13.5Hz, 1H); ESI-MS (m/z):
184 (M++1); Anal. Calcd for (C8H6ClNO2): C, 52.34; H,
3.29; Cl, 19.31; N, 7.63. Found: C, 52.35; H, 3.32; Cl, 19.27;
N, 7.61.
2. 1-chloro-4-((E)-2-nitroprop-1-enyl) benzene (2) (Cornell
et al., 2014): IR (cm−1): 3180, 2980, 1653, 1503, 1397, 1299,
1081, 973, 816; 1H NMR (DMSO-D6,300 MHz): δ 2.37
(s, 3H), 7.30 (d, J = 8.4Hz, 2H), 7.37 (d, J = 8.7Hz, 2H),
7.97 (s, 1H); ESI-MS (m/z): 198 (M++1); Anal. Calcd for
(C9H8ClNO2): C, 54.70; H, 4.08; Cl, 17.94; N, 7.09. Found:
C, 54.67; H, 4.11; Cl, 17.92; N, 7.08.
3. 1-chloro-4-((E)-2-nitrobut-1-enyl) benzene (3): IR (cm−1):
2972, 2935, 1643, 1589, 1549, 1517, 1486, 1302, 1083, 1005,
918, 823, 794; 1HNMR (CDCl3,400MHz): δ 1.27 (t, J 7.6Hz,
3H), 2.84 (q, J = 7.6Hz, 2H), 7.35 (d, J = 8.4Hz, 2H), 7.43 (d,
J = 8.4Hz, 2H), 7.95 (s, 1H); 13C NMR (CDCl3,100MHz):
12.34, 21.05, 112.48, 118.60, 133.15, 135.15, 147.55, 152.21;
ESI-MS (m/z): 212 (M++2), 213 (M++2); Anal. Calcd for
(C10H10ClNO2): C, 56.75; H, 4.76; Cl, 16.75; N, 6.62. Found:
C, 56.78; H, 4.73; Cl, 16.72; N, 6.59.
4. N,N-dimethyl-4-((E)-2-nitrovinyl) benzenamine (4) (Wang
and Wang, 2002): IR (cm−1): 2939, 1574, 1474, 1230, 1061,
963, 796; 1H NMR (DMSO-D6,300 MHz): δ 3.03 (s, 6H),
6.74 (d, J = 8.7Hz, 2H), 7.66 (d, J = 8.7Hz, 2H), 7.96 (d,
J = 13.2Hz, 1H), 8.02 (d, J = 13.2Hz, 1H); ESI-MS (m/z):
193 (M++1); Anal. Calcd for (C10H12N2O2): C, 62.49; H,
6.29; N, 14.57. Found: C, 62.52; H, 6.28; N, 14.55.
5. N,N-dimethyl-4-((E)-2-nitroprop-1-enyl) benzenamine (5)
(Yan et al., 2008): IR (cm−1): 2896, 2358, 1592, 1480, 1359,
1228, 1164, 859, 809; 1H NMR (CDCl3,400 MHz): δ 2.49
(s, 3H), 3.05 (s, 6H), 6.72 (d, J = 9.2Hz, 2H), 7.40 (d, J =
8.0Hz, 2H), 8.08 (s, 1H); ESI-MS (m/z): 207 (M++1); Anal.
Calcd for (C11H14N2O2): C, 64.06; H, 6.84; N, 13.58. Found:
C, 64.02; H, 6.87; N, 13.59.
6. N,N-dimethyl-4-((E)-2-nitrobut-1-enyl) benzenamine (6): IR
(cm−1): 2972, 2364, 1605, 1526, 1056; 1H NMR (CDCl3,400
MHz): δ 1.28 (t, J = 7.2Hz, 3H), 2.93 (q, J = 7.2Hz, 2H), 3.05
(s, 6H), 6.72 (d, J = 9.2Hz, 2H), 7.39 (d, J = 8.8Hz, 2H),
8.03 (s, 1H); ESI-MS (m/z): 220 (M+), 221 (M++1); Anal.
Calcd for (C12H16N2O2): C, 65.43; H, 7.32; N, 12.72. Found:
C, 65.46; H, 7.33; N, 12.68.
7. 1-nitro-4-((E)-2-nitrovinyl) benzene (7) (Kumar et al., 2012):
IR (cm−1): 3110, 2966, 2879, 2358, 1697, 1517; 1H NMR
(CDCl3,400 MHz): δ 7.64-7.70 (m, 2H), 7.87 (d, J = 7.6Hz,
1H), 8.05 (d, J = 13.6Hz, 1H), 8.35 (d, J = 8.4Hz, 2H); ESI-
MS (m/z): 195 (M++1); Anal. Calcd for (C8H6N2O4): C,
49.49; H, 3.12; N, 14.43. Found: C, 49.46; H, 3.09; N, 14.46.
8. 1-nitro-4-((E)-2-nitroprop-1-enyl) benzene (8): IR (cm−1):
2925, 2360, 1692, 1521, 1342, 800; 1H NMR (CDCl3,400
MHz): δ 2.45 (s, 3H), 7.58 (d, J = 8.00Hz, 2H), 8.08 (s,
1H), 8.31 (d, J = 8.70Hz, 2H), ESI-MS (m/z): 208 (M+), 209
(M++1); Anal. Calcd for (C9H8N2O4): C, 51.93; H, 3.87; N,
13.46. Found: C, 51.94; H, 3.91; N, 13.43.
9. 1-nitro-4-((E)-2-nitrobut-1-enyl) benzene (9): IR (cm−1):
2925, 1692, 1521, 1342, 800; 1H NMR (DMSO-D6,300
MHz): δ 1.18 (t, J = 7.20Hz, 3H), 2.78 (q, J = 7.20Hz),
7.81 (d, J = 8.70Hz, 2H), 8.14 (s, 1H), 8.32 (d, J = 8.7Hz,
2H); ESI-MS (m/z): 222 (M+), 223 (M++1); Anal. Calcd for
(C10H10N2O4): C, 54.05; H, 4.54; N, 12.61. Found: C, 54.08;
H, 4.51; N, 12.59.
10. 1-nitro-3-((E)-2-nitrovinyl)benzene (10) (Manna et al., 2013):
IR (cm−1): 3003, 2875, 1694, 1521, 1057, 854; 1H NMR
(CDCl3, 400 MHz): δ 7.51 (t, J = 8.0Hz, 1H), 7.69-7.71 (m,
1H), 7.72 (d, J = 12.0Hz, 1H), 8.07–8.10 (m, 1H), 8.18 (d,
J = 12.0Hz), 8.28 (s, 1H); ESI-MS (m/z): 195 (M++1); Anal.
Calcd for (C8H6N2O4): C, 49.49; H, 3.12; N, 14.43. Found:
C, 49.53; H, 3.07; N, 14.48.
11. 1-nitro-3-((E)-2-nitrobut-1-enyl) benzene (11) (Yan et al.,
2008): IR (cm−1): 3088, 2875, 1664, 1526, 1344, 903, 811,
718; 1H NMR (CDCl3, 400 MHz): δ 2.69 (s, 3H), 7.67 (t, J =
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8.0Hz, 1H), 7.98 (d, J = 7.6Hz, 1H), 8.19 (s, 1H), 8.35 (d, J =
8.00Hz, 1H), 8.39 (s, 1H); ESI-MS (m/z): 209 (M++1); Anal.
Calcd for (C9H8N2O4): C, 51.93; H, 3.87; N, 13.46. Found: C,
51.89; H, 3.97; N, 13.48.
12. 1-nitro-3-((E)-2-nitrobut-1-enyl) benzene (12): IR (cm−1):
2925, 2362, 2327, 1696, 1524, 1344; 1HNMR (DMSO-D6,300
MHz): δ 1.20 (t, J = 7.20Hz, 3H), 2.80 (q, J = 7.2Hz,
2H), 7.80 (t, J = 8.1Hz, 1H), 7.98 (d, J = 7.5Hz, 1H),
8.17 (s, 1H), 8.31 (d, J = 8.10Hz, 1H), 8.37 (s, 1H); 13C
NMR (CDCl3,75MHz): 12.45, 20.74, 124.03, 124.37, 130.19,
130.26, 134.07, 135.17, 148.50, 155.36; ESI-MS (m/z): 222
(M+), 240 (M++18); Anal. Calcd for (C10H10N2O4): C,
54.05; H, 4.54; N, 12.61. Found: C, 54.02; H, 4.57; N, 12.64.
13. 1-methoxy-4-((E)-2-nitrovinyl) benzene (13) (Kumar et al.,
2012): IR (cm−1): 2959, 2924, 2360, 1598, 1506, 1304, 1252,
1167, 1019, 964, 798; 1H NMR (CDCl3,400MHz): δ 3.87 (s,
3H), 6.95 (d, J = 8.4Hz, 2H), 7.50 (d, J = 8.8Hz, 2H), 7.52
(d, J = 13.6Hz, 1H) 7.97 (d, J = 12.8Hz, 1H); ESI-MS (m/z):
180 (M++1); Anal. Calcd for (C9H9NO3): C, 60.33; H, 5.06;
N, 7.82. Found: C, 60.34; H, 5.02; N, 7.84.
14. 1-methoxy-4-((E)-2-nitroprop-1-enyl) benzene (14) (Yan
et al., 2008): IR (cm−1): 2961, 2836, 1601, 1508, 1302, 1252,
1173, 1024, 823; 1H NMR (CDCl3,400 MHz): δ 2.46 (s, 3H),
3.85 (s, 3H), 6.97 (d, J = 8.8Hz, 2H), 7.42 (d, J = 8.4Hz,
2H), 8.06 (s, 1H); ESI-MS (m/z): 194 (M++1); Anal. Calcd
for (C10H11NO3): C, 62.17; H, 5.74; N, 7.25. Found: C, 62.19;
H, 5.71; N, 7.27.
15. 1-methoxy-4-((E)-2-nitrobut-1-enyl) benzene (15): IR
(cm−1): 3104, 2926, 2361, 1596, 1489, 1303, 1244, 1165,
1021, 964, 801; 1H NMR (CDCl3,300 MHz): δ 1.20 (t, J =
7.5Hz, 3H), 281 (q, J = 7.5Hz, 3H), 3.77 (s, 3H), 6.92 (d,
J = 8.7Hz, 2H), 7.33 (d, J = 8.7Hz, 2H), 8.03 (s, 1H); ESI-MS
(m/z): 208 (M++1); Anal. Calcd for (C11H13NO3): C, 63.76;
H, 6.32; N, 6.76. Found: C, 63.73; H, 6.35; N, 6.77.
16. 4-((E)-2-nitrovinyl) phenol (16) (Kumar et al., 2012): IR
(cm−1): 3742, 3134, 3016, 2362, 1695, 1509, 1303, 1228, 1155,
1017, 957, 802, 661; 1H NMR (CDCl3,400 MHz): δ 6.95 (d,
J = 8.4Hz, 2H), 7.49 (d, J = 8.8Hz, 2H), 7.52 (d, J = 13.6Hz,
1H), 7.97 (d, J = 13.6Hz, 1H), 10.46 (brs, 1H); ESI-MS (m/z):
166 (M++1); Anal. Calcd for (C8H7NO3): C, 58.18; H, 4.27;
N, 8.48. Found: C, 58.21; H, 4.24; N, 8.52.
17. 4-((E)-2-nitroprop-1-enyl) phenol (17) (Yan et al., 2008): IR
(cm−1): 3648, 3147, 2956, 2361, 1684, 1513, 1285, 832; 1H
NMR (CDCl3, 400 MHz): δ 2.46 (s, 3H), 5.23 (s, 1H), 6.92
(d, J = 8.4Hz, 2H), 7.38 (d, J = 8.4Hz, 2H), 8.06 (s, 1H);
13C NMR (CDCl3,100 MHz): 14.15, 116.05, 116.25, 123.07,
132.13, 132.43, 134.26, 144.64, 159.80; ESI-MS (m/z): 180
(M++1); Anal. Calcd for (C9H9NO3): C, 60.33; H, 5.06; N,
7.82. Found: C, 60.31; H, 5.04; N, 7.86.
18. 4-((E)-2-nitrobut-1-enyl) phenol (18): IR (cm−1): 3745, 3125,
2983, 2363, 1691, 1516, 1302, 1252, 1173, 1024, 823; 1HNMR
(CDCl3,400 MHz): δ 1.28 (t, J = 6.80Hz, 3H), 2.88 (q, J =
6.4Hz, 2H), 5.37 (s, 1H), 6.92 (d, J = 7.20Hz, 2H), 7.36 (d, J
= 7.20Hz, 2H), 8.00 (s, 1H); ESI-MS (m/z): 194 (M++1);
Anal. Calcd for (C10H11NO3): C, 62.17; H, 5.74; N, 7.25.
Found: C, 62.14; H, 5.76; N, 7.27.
19. 3-((E)-2-nitrovinyl) phenol (19): IR (cm−1): 3351, 3166, 3096,
2809, 2355, 2224, 1592, 1510, 1255, 1020, 959, 809; 1H NMR
(CDCl3,400 MHz): δ 7.40–7.50 (m, 3H), 7.63 (d, J = 7.6Hz,
1H), 7.71 (d, J = 8.0Hz, 1H), 8.06 (d, J = 8.4, 1H); ESI-MS
(m/z): 166 (M++1); Calcd for (C8H7NO3): C, 58.18; H, 4.27;
N, 8.48. Found: C, 58.16; H, 4.29; N, 8.49.
20. 3-((E)-2-nitroprop-1-enyl) phenol (20) (Yan et al., 2008): IR
(cm−1): 3271, 2967, 2927; 1H NMR (DMSO-D6,300 MHz):
δ 2.36 (s, 3H), 5.30 (brs, 1H), 6.72–6.82 (m, 2H), 6.90 (d, J =
7.8Hz, 1H), 7.23 (t, J = 8.1, 8.4Hz, 1H), 7.94 (s, 1H); ESI-MS
(m/z): 180 (M++1); Anal. Calcd for (C9H9NO3): C, 60.33;
H, 5.06; N, 7.82. Found: C, 60.36; H, 5.04; N, 7.79.
21. 3-((E)-2-nitrobut-1-enyl) phenol (21): IR (cm−1): 3741, 3101,
3027, 2923, 2855, 1694, 1521, 1464, 1024, 878, 797; 1H
NMR (CDCl3,400 MHz): δ 1.20 (t, J = 7.20Hz, 3H), 2.79
(q, J = 7.20Hz, 2H), 5.12 (brs, 1H), 6.82–6.84 (m, 2H),
6.92 (d, J = 7.60Hz, 1H), 7.25 (t, J = 7.60Hz, 1H),
7.89 (s, 1H); ESI-MS (m/z): 194 (M++1); Anal. Calcd for
(C10H11NO3): C, 62.17; H, 5.74; N, 7.25. Found: C, 62.20; H,
5.75; N, 7.23.
22. 1,2-dimethoxy-4-((E)-2-nitrovinyl) benzene (22) (Milhazes
et al., 2006): IR (cm−1): 3122, 2357, 1691, 1499, 1335, 1222,
1132, 1009, 967, 798; 1H NMR (DMSO-D6,300 MHz): δ
3.81 (s, 3H), 3.83 (s, 3H), 7.05 (d, J = 8.40Hz, 1H), 7.43
(dd, J = 8.4, 1.8Hz, 1H), 7.49 (s, 1H), 8.06 (d, J = 13.5Hz,
1H), 8.22 (d, J = 13.5Hz, 1H); 13C NMR (CDCl3,100 MHz):
56.03, 56.10, 110.27, 111.36, 122.82, 124.66, 135.18, 139.36,
149.57, 152.83; ESI-MS (m/z): 210 (M++1); ESI-MS (m/z):
224 (M++1); Anal. Calcd for (C10H11NO4): C, 57.41; H,
5.30; N, 6.70. Found: C, 57.42; H, 5.33; N, 6.68.
23. 1,2-dimethoxy-4-((E)-2-nitroprop-1-enyl) benzene (23)
(Milhazes et al., 2006): IR (cm−1): 2959, 2929, 2840, 1650,
1592, 1509, 1448, 1307, 1257, 1136, 1017, 808; 1H NMR
(DMSO-D6,300 MHz): δ 2.42 (s, 3H), 3.81 (s, 3H), 3.84
(s, 3H), 7.02–7.05 (m, 2H), 7.18 (dd, J = 8.4, 1.8Hz, 1H),
8.16 (s, 1H); ESI-MS (m/z): 224 (M++1); Anal. Calcd for
(C11H13NO4): C, 59.19; H, 5.87; N, 6.27. Found: C, 59.22; H,
5.89; N, 6.21.
24. 1,2-dimethoxy-4-((E)-2-nitrobut-1-enyl) benzene (24): IR
(cm−1): 3113, 2889, 1601, 1486, 1300, 1082, 960, 868, 819,
679; 1H NMR (DMSO-D6,300 MHz): δ 1.30 (t, J = 7.5Hz,
3H), 2.91 (q, J = 7.5Hz, 2H), 3.94 (s, 3H), 3.97 (s, 3H), 6.93–
7.00 (m, 2H), 7.09 (dd, J = 8.4, 1.8Hz, 1H), 8.01 (s, 1H);
ESI-MS (m/z): 238 (M++1); Anal. Calcd for (C12H15NO4):
C, 60.75; H, 6.37; N, 5.90. Found: C, 60.71; H, 6.40; N, 5.93.
25. 4-((E)-1-nitroprop-1-en-2-yl)phenol (25): IR (cm−1): 3289,
3066, 2964, 1655, 1567, 1349, 1268, 1207, 1155, 1097, 950,
808, 652; 1H NMR (CDCl3,400 MHz): δ 2.58 (s, 3H), 6.95
(d, J = 8.8Hz, 2H), 7.81 (s, 1H), 7.91(d, J = 8.8Hz, 2H);
ESI-MS (m/z): 180 (M++1); Anal. Calcd for (C9H9NO3): C,
60.33; H, 5.06; N, 7.82. Found: C, 60.29; H, 5.11; N, 7.83.
26. 3-((E)-3-nitropent-2-en-2-yl)phenol (26): IR (cm−1): 3740,
3096, 3051, 3003, 1691, 1519, 1214, 987, 873, 792; 1H NMR
(DMSO-D6, 400 MHz): δ 1.18 (t, J = 6.8Hz, 3H), 2.38 (S,
3H), 2.57 (m, 2H), 6.97 (d, J = 7.2Hz, 1H), 7.23–7.25 (m,
2H), 7.33 (t, J = 7.6Hz, 1H), 9.76 (s, 1H); 13CNMR (DMSO-
D6, 100 MHz): 14.48, 20.11, 26.15, 113.69, 118.22, 130.20,
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136.24, 157.89, 162.76, 168.80, 171.92; ESI-MS (m/z): 208
(M++1); Anal. Calcd for (C11H13NO3): C, 63.76; H, 6.32;
N, 6.76. Found: C, 63.79; H, 6.26; N, 6.78.
27. 2-ethoxy-6-((E)-2-nitrovinyl) phenol (27): IR (cm−1): 3372,
2973, 2359, 1594, 1483, 1336, 1272, 1054, 810; 1H NMR
(CDCl3,400 MHz): δ 1.49 (t, J = 7.2Hz, 3H), 4.16 (q, J
= 7.2Hz, 2H), 6.10 (s, 1H), 6.96–6.98 (m, 2H), 7.12 (dd,
J = 8.4, 1.6Hz, 1H), 7.49 (d, J = 13.2Hz, 1H), 7.94 (d,
J = 13.6Hz, 1H); ESI-MS (m/z): 210 (M++1); Anal. Calcd
for (C10H11NO4): C, 57.41; H, 5.30; N, 6.70. Found: C, 57.43;
H, 5.28; N, 6.72.
28. 3-((E)-2-nitrovinyl)-1H-indole (28): IR (cm−1): 3398, 3100,
2921, 2356, 1608, 1470, 1307, 1229, 1098, 745; 1H NMR
(CDCl3,400 MHz): δ 7.41–7.46 (m, 2H), 7.56-7.58 (m, 1H),
7.77 (d, J = 3.2Hz, 1H), 7.88–7.91 (m, 2H), 8.38 (d, J =
13.2Hz, 1H), 8.87 (brs, 1H); ESI-MS (m/z): 189 (M++1);
Anal. Calcd for (C10H8N2O2): C, 63.82; H, 4.28; N, 14.89.
Found: C, 63.88; H, 4.32; N, 14.82.
29. 3-((E)-2-nitroprop-1-enyl)-1H-indole (29) (Yan et al., 2008):
IR (cm−1): 3420, 3113, 2883, 2359, 1698, 1623, 1519, 1395,
1262, 1212, 1096, 964, 856, 742; 1H NMR (DMSO-D6,300
MHz): δ 2.40 (s, 3H), 7.18–7.28 (m, 2H), 7.51 (d, J = 7.8Hz,
1H), 7.83 (d, J = 7.5Hz, 1H), 8.01 (s, 1H), 8.46 (s, 1H),
12.20 (brs, 1H); 13C NMR (DMSO-D6,100 MHz): 15.07,
108.71, 112.84, 118.69, 121.48, 123.40, 127.08, 127.98, 130.50,
136.64, 141.45; ESI-MS (m/z): 203 (M++1); Anal. Calcd for
(C11H10N2O2): C, 65.34; H, 4.98; N, 13.85. Found: C, 65.38;
H, 5.02; N, 13.82.
30. 3-((E)-2-nitrobut-1-enyl)-1H-indole (30): IR (cm−1): 3307,
2969, 2936, 2354, 1618, 1417, 1256, 1205, 1059, 1004, 934,
731, 683; 1H NMR (CDCl3, 400 MHz): δ 1.31 (t, J = 7.2Hz,
3H), 2.98 (q, J = 7.2Hz, 2H), 7.26-7.35 (m, 2H), 7.47 (d,
J = 8.0Hz, 1H), 7.58 (d, J = 2.0Hz, 1H), 7.82 (d, J = 7.60Hz,
1H), 8.47 (s, 1H), 8.83 (brs, 1H); ESI-MS (m/z): 217 (M++1);
Anal. Calcd for (C12H12N2O2): C, 66.65; H, 5.59; N, 12.96.
Found: C, 66.68; H, 5.62; N, 13.01.
Microbial Strains
One reference each of the following species was used for
their in vitro susceptibility to β-nitrostyrene in this study:
Staphylococcus aureus ATCC 29213, Staphylococcus epidermidis
ATCC 14990, Escherichia coli ATCC 25922, Pseudomonas
aeruginosa ATCC 27853, Candida albicans ATCC 90028,
Candida glabrata ATCC 90030, Aspergillus fumigatus ATCC
16424 and Aspergillus niger ATCC 16404. These strains were
procured from the American Type Culture Collection (ATCC,
Manassas, VA, USA).
Leishmanial Parasite Culture and
Maintenance
L. donovani parasites (MHOM/IN/83/AG83) were maintained
in vivo in BALB/c mice. Promastigotes were routinely cultured at
22◦C in medium M199 supplemented with 10% heat inactivated
fetal bovine serum (FBS, HiMedia Laboratories, Mumbai, India),
penicillin 100 (IU/ml), streptomycin (100µg/ml). Log phase
promastigotes were sub-cultured every 72–96 h, the inoculum
being 2× 106 cells/ml (Afrin et al., 2002).
Cell Line Culture
Murine macrophage cell line, RAW264.7 was grown at 37◦C
in medium RPMI-1640 (pH 7.4, Sigma-Aldrich, St. Louis, MO,
USA) supplemented with 10% heat-inactivated FBS for 48 to
72 h in a humidified atmosphere of 5% CO2 and sub-cultured in
fresh RPMI-1640 medium at an average density 2 × 105 cells/ml
(Islamuddin et al., 2014b).
Antimicrobial Susceptibility Testing Assays
The antibacterial and antifungal activities of the β-nitrostyrenes
were performed by broth microdilution methods as per the
guidelines of Clinical and Laboratory Standard Institute (Wayne,
1998, 2008a,b,c) by using Mueller-Hinton broth (MHB; Becton-
Dickinson, Cockeysville, MD, USA) supplemented with calcium
(25 mg/L) and magnesium (12.5 mg/L) for bacterial strains
while as RPMI 1640 medium with L-glutamine and without
sodium bicarbonate, buffered to pH 7.0 with 0.165M 3-(N-
morpholino) propanesulfonic acid (MOPS; both from Sigma)
was used for fungal strains. Stock solutions were prepared in
100% dimethyl sulfoxide (DMSO; Sigma; distilled water was used
for ciprofloxacin), with a final DMSO concentration of 1% (vol.
per vol.) and two-fold serial dilutions were prepared in media in
amounts of 100µL per well in 96-well U-bottommicrotiter plates
(Tarsons, Kolkata, India) to yield twice the final concentration
required for testing, which ranged from 64 to 0.12µg/mL for
β-nitrostyrenes and 16 to 0.03µg/mL for ciprofloxacin as well
as amphotericin B. Stock inoculum suspensions of the bacteria,
Candida species and Aspergillus species were prepared in sterile
normal saline (0.85%) containing 0.05% polysorbate 20 (NST)
from overnight (3 to 5-day old for Aspergillus species) strains
grown on Trypticase soy agar (TSA; Becton-Dickinson) and
potato dextrose agar (Difco Laboratories, Detroit, MI, USA)
respectively at 35◦C. Inocula were verified for each assay
by plating onto agar plates for colony enumeration. These
suspensions were further diluted in the respective test medium
and a 100µl volume of this diluted inoculum was added to each
well of the plate, resulting in a final inoculum concentration of
approximately 5 × 105 CFU/mL for bacter1ia, (Wayne, 2008a)
approximately 2.5 × 104 CFU/ml for Candida species (Pfaller
et al., 2004) while as 0.4 × 104 to 5 × 104 CFU/mL for
Aspergillus species (Wayne, 2008c). Untreated growth control,
vehicle control (DMSO) and sterility control wells were included
for each isolate tested. Ciprofloxacin and amphotericin B served
as the standard drug controls for bacterial and fungal strains,
respectively. The microtiter plates were incubated at 35◦C for
24 h for bacterial strains and 48 h for fungal strains. The plates
were read visually and the minimum inhibitory concentration
(MIC) was defined as the lowest concentration of test sample that
prevented visible growth with respect to the growth control.
The minimum bactericidal concentration (MBC) and
minimum fungicidal concentration (MFC) were determined by
plating 100µl volumes on agar plates from the wells showing
no visible growth (clear MIC well). The plates were incubated
as described above in MIC measurements. The minimum
concentration of β-nitrostyrenes and drugs that showed ≥99.9%
reduction of the original inoculums was recorded as the MBC as
well as MFC9 (Wayne, 1998; Pfaller et al., 2004). All experiments
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were conducted twice in duplicates on separate occasions with
freshly prepared inoculums and stock solutions.
Anti-leishmanial Activity
Nitrostyrine series were screened for their antileishmanial
activity against L. donovani promastigotes in vitro. Promastigotes
of L. donovani (2 × 106 cells/mL) in M199 medium were
incubated at 22◦C for 72 h with each compound at a
concentration of 100µM. Amphotericin B (AmB) served as
reference drug, 0.2%DMSOwas used as solvent control. Parasites
with media alone were taken as control. Parasite viability was
determined microscopically after 72 h (Islamuddin et al., 2014b).
Dose-Dependent Anti-promastigote
Activity and Determination of IC50
Promastigotes at density of 2 × 106 cells/mL were incubated in
the absence and or presence of most active series of nitrostyrine
(compounds 9, 12, 14, and 18) at serial four-fold dilutions starting
at 25µM (25, 6.25, 1.56, 0.39, 0.097, 0.024, and 0.008µM) for 3
days at 22◦C. AmB was used as a standard antileishmanial drug
control. The cell viability was evaluated by microscopically and
the mean percentage viability was calculated as follows: Mean
cell number of treated parasites / Mean cell number of untreated
parasites × 100. The 50 and 90% inhibitory concentration (IC50
and IC90) i.e., the concentration of drugs that decreased the
cell growth by 50 and 90% respectively was determined by
graphical extrapolation after plotting the graph of % viability vs.
concentration of drug (Islamuddin et al., 2014b).
Leishmanicidal Assay
To confirm the leishmanicidal effect of compounds 9, 12,
14, and 18, treated and untreated parasites (1µM) after 72 h
of incubation, were washed two times with fresh incomplete
medium and finally resuspended in complete media, transferred
back to 22◦C and allowed to grow for 72 h. The viability of the
parasites was determined microscopically (Afrin et al., 2001).
Determination of Promastigote Cellular
Morphology
Changes in the cellular morphology of Leishmania parasites as a
result of compounds 9, 12, 14, and 18 treatment was observed
microscopically. Briefly, the promastigotes (2 × 106 cells/mL)
were incubated in the absence or presence of compounds and
AmB for 72 h at a concentration of 1µM and observed under
40 × objective of a phase-contrast microscope. At least 20
microscopic fields were observed for each sample. Data were
recorded by using NIS-Elements imaging software (Paris et al.,
2004).
Anti-amastigote Activity and Nitrite
Production in an Ex-vivo Macrophage
Model
Macrophages from the peritonial cavity of BALB/c mice (1× 106
cellsml−1) were allowed to adhere to round glass coverslips in a
24 well tissue culture plate and incubated for 12 h at 37◦C in a
CO2 incubator. After removal of the non-adherent macrophages,
the cells were infected with stationary phase promastigotes using
a cell to parasite ratio of 1:10 and incubated at 37◦C for 24 h. The
non-phagocytosed parasites were removed by washing, and the
infected macrophages incubated with the test compounds 9, 12,
14, and 18 (0–25µM) for an additional 48 h. The coverslips were
fixed in methanol and giemsa-stained for microscopic evaluation
(100X) of amastigote infectivity. Number of amastigotes per
100 macrophages were enumerated and the concentration that
decreased amastigotes by 50% (IC50) was determined (Wong
et al., 2012; Islamuddin et al., 2014a).
The supernatant from control L. donovani infected and
treated macrophages were analyzed for nitrite content
by the Griess reaction. In brief, equal volume of Griess
reagent [1%sulphanilamide and 0.1% N-(1-naphthyl)
ethylenediaminedihydrochloride in 5% phosphoric acid]
was added to the culture supernatant and the plates were
incubated for 10min at room temperature using sodium nitrite
as a standard. The absorbance at 550 nm was measured and the
concentration of nitrite was calculated by a linear regression
analyzing the standard curve generated with sodium nitrite
(Varela et al., 2012).
Ex vivo Cytotoxicity Assay
To evaluate the adverse toxicity of test compounds (9, 12, 14,
and 18) on mammalian cells, the murine macrophage cell line
(RAW264.7) cultured in RPMI 1640 medium were exposed to
increasing concentrations of test compounds (5–50µM) at 37◦C,
5% CO2 for 48 h. AmB as the reference drug, and macrophages
without any treatment were taken as control. The percentage of
cell viability was evaluated by MTT (3-{4, 5-dimethylthiazol-2-
yl}-2, 5-diphenyltetrazoliumbromide) assay (Das et al., 2008).
Statistical Analysis
In vitro antileishmanial activity was expressed as IC50 by linear
regression analysis. Values are mean± SE of samples in triplicate
from at least three independent experiments. Statistical analysis
was performed using ANOVA followed by Dunnett’s test. ∗P <
0.05, ∗∗P < 0.01 and ∗∗∗P < 0.001 compared with the untreated
control group were considered significant.
RESULTS
Chemistry
β-Nitrostyrene derivatives were prepared by a widely used
Henry reaction (Gairaud and Lappin, 1953; Huitric et al., 1956;
Milhazes et al., 2006; by a nitroaldol condensation reaction-
Henry reaction). The compounds were synthesized by the
reaction of aromatic aldehydes/ketones with nitromethane/
nitroethane/nitropropane in presence of ammonium acetate in
acetic acid. These experimental conditions led to moderate to
high yields of the target molecules. The final products were
identified by NMR (1H NMR), FT-IR and MS-EI spectroscopic
techniques. These compounds have been assigned as E-isomers
based on the coupling constants and the existing literature
(Scheme 1).
A series of β-nitrostyrene derivatives were synthesized
(Table 1) in order to study the influence of different aromatic
substitution patterns and alkyl substitutions at α/β positions
Frontiers in Microbiology | www.frontiersin.org 6 September 2016 | Volume 7 | Article 1379
Shafi et al. β-Nitrostyrenes as Anti-leishmanial Agents
on the antimicrobial/anti-leishmanial activities. Melting points
and NMR data of the synthesized β-nitrostyrenes were
consistent with the literature values (Gairaud and Lappin, 1953;
Somasekhara et al., 1971; Bose et al., 1992;Wang andWang, 2002;
Al-Zereini et al., 2007; Yan et al., 2008; Kumar et al., 2012; Manna
et al., 2013; Cornell et al., 2014).
SCHEME 1 | Synthesis.
In vitro Antimicrobial Susceptibility Results
All the above synthesized β-nitrostyrenes were tested for their
in vitro antibacterial as well as antifungal activities against
two references of strains of each (total eight strains) selected
gram-positive bacteria, gram-negative bacteria, Candida and
Aspergillus species by broth microdilution method following
Clinical and Laboratory Standards Institute (CLSI) guidelines.
The results are tabulated in Tables 2, 3.
Compound 12 exhibited broad-spectrum and potent activity
against a variety of selected pathogenic strains, with the MIC
ranging from 0.25 to 0.5µg/mL for gram-positive bacteria
(S. aureus and S. epidermidis), 16µg/mL for both strains of E. coli
and P. aeruginosa (Gram-negative bacteria), 0.25 to 2.0µg/mL
for Candida species and 0.5 to 1.0µg/mL for Aspergillus species,
respectively.
It was observed that all tested strains were susceptible to
compounds 3, 7, 9, 17, 18, 20, and 21. These compounds exhibited
TABLE 1 | Synthetic library of β-nitrostyrenes.
Compound Basic moiety R R' R'' Yields a (%) M.P. (◦C) M.P. reference
1 4-Cl H H 81 112–114 113–114
2 4-Cl H Me 82 88–90 89–91
3 4-Cl H Et 80 105–107
4 4-NMe2 H H 91 186–188 186–188
5 4-NMe2 H Me 96 90–91
6 4-NMe2 H Et 92 77–79
7 4-NO2 H H 90 94–96 94–96
8
NO2
R
R''
R' 4-NO2 H Me 89 114–116 114–115
9 4-NO2 H Et 81 104–106 103.5–104.5
10 3-NO2 H H 79 124–126 125
11 3-NO2 H Me 81 80–82
12 3-NO2 H Et 84 84–86
13 4-OMe H H 89 86–88 85–87
14 4-OMe H Me 88 44–46 44–45
15 4-OMe H Et 73 Oil Oil
16 4-OH H H 76 168–169 167–171b
17 4-OH H Me 72 122–124 124–125
18 4-OH H Et 71 60–62
19 3-OH H H 79 138–140 136–140b
20 3-OH H Me 81 96–98 96–98
21 3-OH H Et 79 82–84
22 3,4-dimethoxy H H 88 140–142 142–144
23 3,4-dimethoxy H Me 89 70–72 71–72
24 3,4-dimethoxy H Et 91 78–80 78–79
25 4-OH Me H 77 88–90
26 3-OH Me Et 74 138–140
27 2-OH,3-OEt H H 87 128–130
28
N
H
R'
R''
NO2 - H H 89 134–136
29 - H Me 91 182–184
30 - H Et 86 64–66
a Isolated yields.
bMelting points of compounds from sigma aldrich.
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TABLE 2 | In vitro antibacteriall activity of β-Nitrostyrene.
Test compounds Antibacterial activity-MIC in (µg/mL)
Sa Se Ec Pa
ATCC 29213 ATCC 14990 ATCC 25922 ATCC 27853
MIC MBC MIC MBC MIC MBC MIC MBC
Cipro 0.25 0.5 0.25 0.25 <0.03 <0.03 0.25 1.0
1 32 32 16 16 32 32 32 64
2 >64 >64 32 32 >64 >64 >64 >64
3 4 4 2 2 >64 >64 >64 >64
4 >64 >64 >64 >64 >64 >64 >64 >64
5 >64 >64 >64 >64 >64 >64 >64 >64
6 >64 >64 >64 >64 >64 >64 >64 >64
7 8 8 4 4 16 32 16 32
8 16 32 16 16 64 >64 64 >64
9 8 8 4 4 16 32 16 32
10 NT NT NT NT NT NT NT NT
11 8 16 8 8 32 64 64 >64
12 0.5 0.5 0.25 0.25 16 16 16 16
13 64 64 32 32 >64 >64 >64 >64
14 8 8 4 4 64 >64 >64 >64
15 16 32 16 16 >64 >64 >64 >64
16 64 >64 64 64 64 >64 >64 >64
17 4 4 2 2 16 16 16 32
18 8 16* 8 8 >64 >64 >64 >64
19 >64 >64 64 >64 >64 >64 >64 >64
20 2 4 2 2 16 16 16 32
21 2 4 2 2 32 64 32 64
22 >64 >64 64 64 >64 >64 >64 >64
23 8 16 8 8 >64 >64 >64 >64
24 NT NT NT NT NT NT NT NT
25 NT NT NT NT NT NT NT NT
26 8 16 8 8 >64 >64 >64 >64
27 32 32 16 16 >64 >64 >64 >64
28 64 >64 64 64 64 >64 >64 >64
29 16 16 8 8 >64 >64 >64 >64
30 16 16 8 8 64 >64 >64 >64
NT, not tested; Sa, Staphylococcus aureus; Se, Staphylococcus epidermidis; Ec, Escherichia coli; Pa, Pseudomonas aeruginosa; MIC, minimum inhibitory concentration; MBC, minimum
bactericidal concentration; Ciprofloxacin served as drug control for bacterial strains. The results are representative of two separate experiments performed in duplicate and similar results
were observed each time.
the minimum inhibitory concentration (MIC) ranging from
2 to 32µg/mL for S. aureus, 2–16µg/mL for S. epidermidis,
16–32µg/mL for both strains of E. coli and P. aeruginosa,
4–32µg/mL for C. albicans, 0.25–16µg/mL for C. glabrata,
4–8µg/mL for A. fumigatus and 2–4µg/mL for A. niger,
respectively.
The minimum bactericidal concentrations (MBCs) were
found to be either same or only two-fold greater than MICs and
the minimum fungicidal concentrations (MFCs) were also found
to be either same or only two-fold greaterthan MICs, which
indicates that β-nitrostyrenes have microbicidal effect against all
tested species. Among all the fungal species tested, C. glabrata
(MIC and MFC were 0.25µg/mL for compound 9 as well as
12, respectively) was found to be the most susceptible species.
One percent DMSO (vehicle control) had no inhibitory effect on
the growth of tested fungal species, when compared with growth
control.
Anti-leishmanial Effect
L. donovani promastigotes were treated with β-nitrostyrenes
(100µM) and their viability ascertained under phase contrast
microscope (40X). All the parasites were found to be dead when
treated with compounds 7, 8, 9, 11, 12, 14, 17, 18, 20, 21, 23; while
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TABLE 3 | In vitro antifungal activity of β-Nitrostyrenes.
Test compounds Antifungal activity-MIC in (µg/mL)
Ca Cg Af An
ATCC 90028 ATCC 90030 ATCC 16424 ATCC 16404
MIC MFC MIC MFC MIC MFC MIC MFC
AmB 0.5 0.5 0.5 0.5 0.5 1.0 1.0 1.0
1 32 32 4 4 8 8 4 4
2 >64 >64 32 32 >64 >64 64 >64
3 >64 >64 >64 >64 32 64 32 32
4 >64 >64 32 32 64 >64 64 >64
5 >64 >64 32 32 >64 >64 64 >64
6 >64 >64 32 32 >64 >64 64 >64
7 4 4 4 4 4 4 2 2
8 4 4 1 1 4 4 2 2
9 8 8 0.25 0.25 8 8 4 4
10 NT NT NT NT NT NT NT NT
11 NT NT NT NT NT NT NT NT
12 2 2 0.25 0.25 1 1 0.5 0.5
13 64 64 32 32 64 >64 64 64
14 32 32 8 8 8 8 4 4
15 32 32 16 16 8 16 8 8
16 32 32 16 16 16 16 8 16
17 8 8 8 8 8 8 4 4
18 16 16 8 8 8 16 4 8
19 64 >64 16 16 64 >64 64 64
20 16 16 8 8 8 8 4 4
21 32 32 16 16 8 8 4 8
22 64 64 16 16 32 64 32 32
23 32 32 4 4 16 16 8 8
24 NT NT NT NT NT NT NT NT
25 NT NT NT NT NT NT NT NT
26 >64 >64 >64 >64 >64 >64 64 >64
27 32 32 16 16 16 16 8 8
28 32 32 16 16 16 16 8 16
29 64 64 8 8 16 16 8 8
30 >64 >64 32 64 64 64 32 32
NT, not tested; Ca, Candida albicans; Cg, Candida glabrata; Af, Aspergillus fumigatus; An, Aspergillus niger; MIC, minimum inhibitory concentration; MFC, minimum fungicidal
concentration. Aamphotericin B was used as drug control for fungal strains. The results are representative of two separate experiments performed in duplicate and similar results
were observed each time.
few parasites survived with rest of the compounds after 72 h of
incubation.
IC50 and IC90 Values of Selected
Compounds Against L. donovani
Promastigotes
The compounds (7, 8, 9, 11, 12, 14, 17, 18, 20, 21, and 23)
with potent anti-leishmanial activity (from the above anti-
leishmanial susceptibility results) were further evaluated for their
50 and 90% growth inhibitory effect. Treatment with these
compounds demonstrated a dose dependent killing effect on
the promastigotes. Fifty percent inhibitory concentration of the
compounds is depicted in the Table 4 where compounds 9, 12,
14, and 18 were found to be more potent, exhibiting IC50 in nM
range. The 50 and 90% inhibitory concentration of the highly
potent compounds (9, 12, 14, and 18) is represented in Figure 2.
The established anti-leishmanial drug AmB served as a positive
drug control, showed a similar trend in dose dependent parasite
killing with IC50 and IC90 values at 19.60 ± 1.71 and 82.56 ±
1.36 nM respectively. Parasite viability was not affected by DMSO
(0.2%, data not shown) used as solvent control.
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TABLE 4 | In vitro antileishmanial activities of β-Nitrostyrenes 9, 12, 14, 18, and AmB against L. donovani promastigotes and intracellular amastigotes.
S.No Compound L. donovani promastigotes L. donovani promastigotes L. donovani amastigotes
IC90 ± SEM (nM)
a IC50 ± SEM (nM)
a IC50 ± SEM (nM)a
1 9 90.16 ± 1.11 23.40 ± 0.71 30.5 ± 3.42
2 12 86.46 ± 0.21 37.83 ± 3.74 21.46 ± 0.96
3 14 89.00 ± 0.52 40.50 ± 1.47 26.43 ± 2.71
4 18 320.50 ± 3.65 55.66 ± 2.84 61.63 ± 8.02
5 AmB 82.56 ± 1.36 19.60 ± 1.71 27.83 ± 3.26
SEM, Standard Error of the Mean; aMean from three determinations.
FIGURE 2 | Estimation of IC50 and IC90 of Compounds 9, 12, 14, and 18
against promastigotes. Parasites (2× 106 cells/mL) were incubated with
serial four-fold dilutions of test compounds (starting at 25µM) for 72 h and
viability was determined microscopically, as described in methods. Each point
or bar corresponds to the mean ± SE of triplicate samples and is
representative of one of three independent experiments.
Leishmanicidal Effect of the Treated
Compounds
To determine the lethal effects of compounds 9, 12, 14, and
18 on promastigotes, treated and untreated parasites after
72 h were washed and resuspended in fresh media. After an
additional 72 h in culture, the parasites did not revert back to
their normal morphology and still appeared dead in case of
prior incubation with 9, 12, 14, and 18, as also observed in
positive drug control (AmB), confirming their leishmanicidal
effects. Untreated control promastigotes reverted to late log phase
(Figure 3A).
Cellular Morphological Alterations in
L. donovani Promastigotes
Microscopic assessment of promastigotes upon treatment with
compounds 9, 12, 14, and 18 at 1µM revealed that the parasites
altered to an ovoid shape with cell shrinkage, loss of flagella,
cytoplasmic condensation, resulting in complete circularization
of the promastigotes and substantial reduction in size compared
FIGURE 3 | (A) Leishmanicidal effects of treated promastigotes with compounds 9, 12, 14, and 18 revealed no reversion of growth. Each point or bar corresponds to
the mean ± SE of triplicate samples and is representative of one of three independent experiments. (B) Analysis of cellular morphology of promastigotes treated with
compounds 9, 12, 14, 18 and ampotericin B. Exponential-phase promastigotes (2× 106 cells/mL) were incubated with 1µM of compounds 9, 12, 14, 18 for 72 h and
analyzed by light microscopy (400 magnification), as described in Methods.
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FIGURE 4 | Effects of β-nitrostyrenes (9, 12, 14, and 18) compounds on L. donovani intracellular amastigote forms. After infection with promastigotes,
peritoneal macrophages were incubated with serial four-fold dilutions of β-nitrostyrenes compounds (starting at 25000-0 nM) for 48 h and infection (A) as a percentage
of control, (B) as number of amastigotes per 100 macrophages) was determined microscopically, as described in Methods. Each point corresponds to the mean ±
SE of triplicate samples and is representative of one of three independent experiments.
to the untreated control. These changes, typical of programmed
cell death (Figure 3B) were also observed in AmB treated
parasites.
Effect of Test Compounds (9, 12, 14, and
18) on L. donovani Intracellular Amastigote
Forms
Most active compounds against promostigotes were selected
for the further studies against intracellurar amastigotes.
Anti-amastigote activity of β-nitrostyrenes (9, 12, 14, and
18) on phagocytosed amastigotes within the macrophages
was determined by giemsa stain method under microscopic
observation. Compounds 9, 12, 14, and 18 demonstrated a
high degree of activity with IC50 30.5 ± 3.42, 21.46 ± 0.96,
26.43 ± 2.71 and 61.63 ± 8.02 nM respectively (Table 4)
when compared to the standard AmB (27.83 ± 3.26 nM).
Giemsa-stained micrographs of infected macrophages showed
almost total clearance of the intracellular amastigotes at the
highest dose of 1.56µM, similar effect was observed with AmB
(Figure 4).
β-Nitrostyrenes (9, 12, 14, and 18) Induced
Nitric Oxide Production in Ex vivo Model
Nitric oxide (NO) levels were estimated in the culture
supernatants of normal macrophages and infected macrophages.
Infected macrophages demonstrated low basal levels of NO
confirming the disease progression. NO level of 9, 12, 14, and
18 treated macrophages were estimated by using giess method
at 0–25µM concentrations for 48 h. A mild increase in NO
production was observed with compounds 9 (8.05µM) and 12
(7.89µM) followed by compound 14 (5.89µM), 18 (3.22µM)
FIGURE 5 | β-Nitrostyrenes (9, 12, 14, and 18) induced nitric oxide
production in ex vivo model. Macrophages isolated from peritoneal cavity of
BALB/c mice, infected with promastigotes and stimulated with β-nitrostyrenes
(9, 12, 14, and 18) compounds at 37◦C in a CO2 incubator with serial four-fold
dilutions of test compounds (starting at 25–0 µM) for 48 h. Nitrite generation
was determined by Gries methods, as described in Methods. Each point
corresponds to the mean ± SE of triplicate samples and is representative of
one of three independent experiments.
and the standard AmB (3.81) at higher concentration (25µM;
Figure 5).
Cytotoxicity of the Test Compounds (9, 12,
14, and 18) on RAW264.7 Macrophage Cell
Line
In vitro cytotoxicity assay was carried out with macrophage
cell line RAW264.7 to investigate the side effects of the test
compounds using AmB as a reference drug. The toxicity assay
revealed that test compounds up to 10µM had no adverse effects
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on the viability and morphology of the macrophages unlike the
standard drug, AmB (Figure 6).
DISCUSSION
VL is considered as an opportunistic infection among
immunocompromised patients and mainly treated with toxic
pentavalent antimonials, second line drugs such as amphotericin
B and pentamidine. Due to severe adverse and toxic profile of
synthetic molecules, there is an essential requirement of new,
safer and active principles from nature (Sundar et al., 2000).
Hence natural products once again got the attention and several
groups are working on the development of natural product
based new anti-leishmanial agents (Barata et al., 2000; Rocha
et al., 2005; Sharma et al., 2013; Islamuddin et al., 2014a,b;
Jameel et al., 2014; Rottini et al., 2015). Over the years several
antifungal and anticancer agents were screened for their anti-
leishmanial potentials. Though there are some positive results
obtained but they also suffered with acquired resistance and
toxicity. Hence the search for new potential anti-leishmanial
agents with better safety profiles from natural sources is being
continued and is one of the core challenges in the current drug
discovery.
In this regard we have selected antimicrobial β-nitrostyrenes
to evaluate their anti-leishmanial potentials. Inspired by the
naturally occurring β-nitrostyrenes, a focused library of thirty
β-nitrostyrenes was synthesized by varying nature and position
of substitution over the aromatic ring and the nature of
alkyl chain at β-position. All the synthesized compounds were
tested for their antibacterial, antifungal, and antileishmanial
activities. Close congeners (compound 9, 12, 14, and 18) of the
naturally occurring β-nitrostyrenes were found to be most active
amongst the compounds tested (Figure 7) against both the both
forms of L. donovani i.e., Promastigotes and amastigotes. These
compounds have demonstrated more or less similar degree of
activity against the both forms (Promastigotes and amastigotes).
From the results a SAR can be clearly depicted based on the
substitution of aromatic moiety and the nature of the alkyl side
chain on α and β positions of the β-nitrostyrenes (Figure 8).
From the data it is clearly understood that the alkyl substitution
at β position highly influences the biological activity against L.
donovani promastigotes and amastigotes. Increase in the chain
length leads to the improvement in the activity. Ethyl substitution
at β position shows the highest degree of anti-leishmanial activity.
The order of activity with respect to alkyl substitution at β
position is H<Me< Et.
The activity has been also altered moderately based on the
nature and position of the substituent on the aromatic ring.
Para-substituted compounds were found to be more active than
meta-substituted compounds. Nitro substitution on aromatic
ring exerted better activity than the electron donor groups.
Substitution of nitro group at para/meta position with ethyl
group at β position highly enhanced the activity (compounds
9 and 12, IC50 = 23.40 ± 0.71 and 37.83 ± 3.74 nM against
promastigotes and 30.5 ± 3.42, 21.46 ± 0.96 nM against
amastigotes respectively). Among electron donor substituents
FIGURE 6 | Absence of adverse toxicity of test compounds 9, 12, 14,
and 18 on macrophage cell line RAW264.7. The cell lines were incubated
for 48 h at 37◦C in a CO2 incubator with increasing concentrations of test
compounds or AmB and viability was ascertained. Each point or bar
corresponds to the mean ± SE of triplicate samples and is representative of
one of three independent experiments.
4-OMe, 4-OH substituents exhibited better activity. Compound
14 with methoxy substitution at the para-position of the aromatic
system and methyl group at β-position of the β-nitrostyrene have
shown the prominent anti-leishmanial activity with IC50 40.50±
1.47 and 26.43± 2.71 nM (against promastigotes and amastigotes
respectively) whereas ethyl substitution at β-position reduced the
activity (compound 15). Introduction of another methoxy group
at the ortho position of 4-methoxy β-methyl β-nitrostyrenes
(23) decreased the activity (showed moderate activity) while
3,4-dimethoxy β-nitrostyrene (22) and 3,4-dimethoxy β-ethyl
β-nitrostyrenes (24) were found to be inactive.
Hydroxy group at para-position of the aromatic ring with
ethyl substitution at β-position of β-nitrostyrene (Compound
18) resulted in the significant anti-leishmanial activity with
IC50 55.66 ± 2.84 nM when compared to meta-substitution
(compound 21) (IC50 28.42 ± 3.11µM) against promastigates.
Compound 18 also exhibited the similar activity profile against
amastigotes with IC50 61.63 ± 8.02 nM. While 4-hydroxy and 3-
hydroxy β-nitrostyrenes with methyl substitution at β-position
(compounds 17 and 20) were moderately active (IC50s 39.36
± 1.36 and 63.24 ± 2.06µM respectively). Methyl substitution
at α-position of the 4-hydroxy β-methyl /3-hydroxy β-ethyl
nitrostyrenes (compounds 25, 26) resulted in the loss of activity.
Other β-ethyl nitrostyrenes with Cl, N, N-dimethyl amino and
2-hydroxy-3-ethoxy substitutions (1–6, 27) were found to be
inactive. Hetero aromatic nitro vinyl derivatives (indole based)
were also been evaluated for their anti-leishmanial potentials.
Irrespective of the β-chain elongation these compounds (28–30)
were found to be inactive. Toxicity studies against macrophages
reveal that these compounds were found to be insignificantly
toxic when compared to standard AmB even at 25µM
concentrations.
NO estimation experiments further reveals the moderate
increase in the NO expression levels. Among the compounds
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FIGURE 7 | Diversity oriented synthesis of natural products inspired β-nitrostyrene library.
FIGURE 8 | Structure-activity relationship of β-nitrostyrenes.
tested, compounds 9 and 12 moderately increased the NO levels
while NO levels were mildly induced by compound 14.
CONCLUSION
In conclusion, a focused library of thirty β-nitrostyrenes
has been synthesized and was tested against eight reference
strains of selected pathogenic organisms and L. donovani
promastigotes. Some of these compounds showed a broad
spectrum of antimicrobial activity. Compounds 9, 12, 14, and
18 were found to be highly active against both forms of
L. donovani promastigotes and intracellular amastigotes (nM
range) and comparable with the standard drug AmB. Further
these compounds were found to be insignificantly toxic against
mammalian macrophages even at a concentration of 25µM.
With the credentials of high degree of activity, safety profiles,
and economic methods for the synthesis, this class of compounds
may be potential candidates for further drug development against
leishmaniasis. Detailed investigation of mechanistic studies is in
progress.
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